Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) EPS (Basic) (2016 - 2025)

Arcadia Biosciences filings provide 12 years of EPS (Basic) readings, the most recent being -$0.98 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 80.24% to -$0.98 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.71, a 71.78% increase, with the full-year FY2025 number at -$1.71, up 66.92% from a year prior.
  • EPS (Basic) hit -$0.98 in Q4 2025 for Arcadia Biosciences, down from $0.63 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $2.33 in Q2 2023 to a low of -$27.3 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was -$1.54 (2023), compared with a mean of -$3.8.
  • Biggest five-year swings in EPS (Basic): crashed 7454.55% in 2022 and later skyrocketed 371.43% in 2025.
  • Arcadia Biosciences' EPS (Basic) stood at -$27.3 in 2021, then soared by 83.08% to -$4.62 in 2022, then plummeted by 56.06% to -$7.21 in 2023, then skyrocketed by 31.21% to -$4.96 in 2024, then skyrocketed by 80.24% to -$0.98 in 2025.
  • The last three reported values for EPS (Basic) were -$0.98 (Q4 2025), $0.63 (Q3 2025), and -$3.26 (Q2 2025) per Business Quant data.